nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—CHRM3—ureter—prostate cancer	0.0695	0.372	CbGeAlD
Mivacurium—CHRNA1—prostate gland—prostate cancer	0.0201	0.108	CbGeAlD
Mivacurium—CHRNA2—prostate gland—prostate cancer	0.0167	0.0893	CbGeAlD
Mivacurium—CHRNB1—prostate gland—prostate cancer	0.0155	0.0831	CbGeAlD
Mivacurium—CHRM2—prostate gland—prostate cancer	0.00995	0.0533	CbGeAlD
Mivacurium—CHRM3—prostate gland—prostate cancer	0.0081	0.0434	CbGeAlD
Mivacurium—CHRNB1—testis—prostate cancer	0.00684	0.0366	CbGeAlD
Mivacurium—BCHE—prostate gland—prostate cancer	0.00661	0.0354	CbGeAlD
Mivacurium—BCHE—seminal vesicle—prostate cancer	0.00559	0.0299	CbGeAlD
Mivacurium—CHRM3—renal system—prostate cancer	0.00552	0.0296	CbGeAlD
Mivacurium—CHRM3—urethra—prostate cancer	0.00543	0.029	CbGeAlD
Mivacurium—CHRNB1—lymph node—prostate cancer	0.00496	0.0265	CbGeAlD
Mivacurium—Angiopathy—Degarelix—prostate cancer	0.0047	0.00794	CcSEcCtD
Mivacurium—Immune system disorder—Degarelix—prostate cancer	0.00468	0.00791	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Abiraterone—prostate cancer	0.00467	0.0079	CcSEcCtD
Mivacurium—Mediastinal disorder—Degarelix—prostate cancer	0.00467	0.00789	CcSEcCtD
Mivacurium—Arrhythmia—Degarelix—prostate cancer	0.00463	0.00782	CcSEcCtD
Mivacurium—Muscle spasms—Estradiol valerate/Dienogest—prostate cancer	0.00456	0.00771	CcSEcCtD
Mivacurium—Flushing—Cabazitaxel—prostate cancer	0.00453	0.00766	CcSEcCtD
Mivacurium—Cardiac disorder—Cabazitaxel—prostate cancer	0.00453	0.00766	CcSEcCtD
Mivacurium—Erythema—Degarelix—prostate cancer	0.00451	0.00762	CcSEcCtD
Mivacurium—Anaphylactic shock—Estrone—prostate cancer	0.00443	0.0075	CcSEcCtD
Mivacurium—Angiopathy—Cabazitaxel—prostate cancer	0.00443	0.00748	CcSEcCtD
Mivacurium—Immune system disorder—Cabazitaxel—prostate cancer	0.00441	0.00745	CcSEcCtD
Mivacurium—Mediastinal disorder—Cabazitaxel—prostate cancer	0.0044	0.00743	CcSEcCtD
Mivacurium—Skin disorder—Abiraterone—prostate cancer	0.00438	0.0074	CcSEcCtD
Mivacurium—Arrhythmia—Cabazitaxel—prostate cancer	0.00436	0.00737	CcSEcCtD
Mivacurium—Muscle spasms—Degarelix—prostate cancer	0.00433	0.00733	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Conjugated Estrogens—prostate cancer	0.00431	0.00728	CcSEcCtD
Mivacurium—Bradycardia—Bicalutamide—prostate cancer	0.00426	0.0072	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Flutamide—prostate cancer	0.00425	0.00718	CcSEcCtD
Mivacurium—Erythema—Cabazitaxel—prostate cancer	0.00425	0.00718	CcSEcCtD
Mivacurium—Muscle spasms—Cabazitaxel—prostate cancer	0.00408	0.0069	CcSEcCtD
Mivacurium—Skin disorder—Flutamide—prostate cancer	0.00398	0.00673	CcSEcCtD
Mivacurium—Cardiac disorder—Bicalutamide—prostate cancer	0.00388	0.00657	CcSEcCtD
Mivacurium—Phlebitis—Estradiol—prostate cancer	0.00387	0.00655	CcSEcCtD
Mivacurium—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.00387	0.00654	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Degarelix—prostate cancer	0.00381	0.00644	CcSEcCtD
Mivacurium—Angiopathy—Bicalutamide—prostate cancer	0.0038	0.00642	CcSEcCtD
Mivacurium—Immune system disorder—Bicalutamide—prostate cancer	0.00378	0.00639	CcSEcCtD
Mivacurium—Mediastinal disorder—Bicalutamide—prostate cancer	0.00377	0.00638	CcSEcCtD
Mivacurium—Arrhythmia—Bicalutamide—prostate cancer	0.00374	0.00632	CcSEcCtD
Mivacurium—Anaphylactic shock—Degarelix—prostate cancer	0.00368	0.00622	CcSEcCtD
Mivacurium—Phlebitis—Mitoxantrone—prostate cancer	0.00361	0.0061	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.00359	0.00607	CcSEcCtD
Mivacurium—Skin disorder—Degarelix—prostate cancer	0.00357	0.00604	CcSEcCtD
Mivacurium—CHRM3—testis—prostate cancer	0.00357	0.0191	CbGeAlD
Mivacurium—Bronchospasm—Conjugated Estrogens—prostate cancer	0.00354	0.00599	CcSEcCtD
Mivacurium—Urticaria—Estrone—prostate cancer	0.00352	0.00596	CcSEcCtD
Mivacurium—Muscle spasms—Bicalutamide—prostate cancer	0.0035	0.00592	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Estradiol—prostate cancer	0.00345	0.00583	CcSEcCtD
Mivacurium—Hypotension—Degarelix—prostate cancer	0.00344	0.00581	CcSEcCtD
Mivacurium—BCHE—bone marrow—prostate cancer	0.00341	0.0182	CbGeAlD
Mivacurium—Tachycardia—Cabazitaxel—prostate cancer	0.00338	0.00572	CcSEcCtD
Mivacurium—Skin disorder—Cabazitaxel—prostate cancer	0.00337	0.00569	CcSEcCtD
Mivacurium—Hypotension—Cabazitaxel—prostate cancer	0.00324	0.00548	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Mitoxantrone—prostate cancer	0.00321	0.00543	CcSEcCtD
Mivacurium—Angiopathy—Ethinyl Estradiol—prostate cancer	0.00321	0.00543	CcSEcCtD
Mivacurium—Immune system disorder—Ethinyl Estradiol—prostate cancer	0.0032	0.0054	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.00308	0.00521	CcSEcCtD
Mivacurium—Urticaria—Estradiol valerate/Dienogest—prostate cancer	0.00307	0.0052	CcSEcCtD
Mivacurium—Phlebitis—Etoposide—prostate cancer	0.003	0.00507	CcSEcCtD
Mivacurium—Muscle spasms—Ethinyl Estradiol—prostate cancer	0.00296	0.00501	CcSEcCtD
Mivacurium—Injection site reaction—Docetaxel—prostate cancer	0.00294	0.00498	CcSEcCtD
Mivacurium—Dizziness—Estrone—prostate cancer	0.00293	0.00496	CcSEcCtD
Mivacurium—Rash—Estramustine—prostate cancer	0.00293	0.00495	CcSEcCtD
Mivacurium—Dermatitis—Estramustine—prostate cancer	0.00292	0.00494	CcSEcCtD
Mivacurium—Urticaria—Degarelix—prostate cancer	0.00292	0.00494	CcSEcCtD
Mivacurium—BCHE—testis—prostate cancer	0.00291	0.0156	CbGeAlD
Mivacurium—Skin disorder—Bicalutamide—prostate cancer	0.00289	0.00488	CcSEcCtD
Mivacurium—Injection site reaction—Capecitabine—prostate cancer	0.00285	0.00482	CcSEcCtD
Mivacurium—Rash—Abiraterone—prostate cancer	0.00284	0.00481	CcSEcCtD
Mivacurium—Dermatitis—Abiraterone—prostate cancer	0.00284	0.0048	CcSEcCtD
Mivacurium—Bronchospasm—Estradiol—prostate cancer	0.00284	0.0048	CcSEcCtD
Mivacurium—Rash—Estrone—prostate cancer	0.0028	0.00473	CcSEcCtD
Mivacurium—Dermatitis—Estrone—prostate cancer	0.00279	0.00472	CcSEcCtD
Mivacurium—Dizziness—Nilutamide—prostate cancer	0.00272	0.0046	CcSEcCtD
Mivacurium—Dizziness—Flutamide—prostate cancer	0.00271	0.00458	CcSEcCtD
Mivacurium—Cardiac disorder—Goserelin—prostate cancer	0.0027	0.00457	CcSEcCtD
Mivacurium—Cardiac disorder—Conjugated Estrogens—prostate cancer	0.00268	0.00452	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Etoposide—prostate cancer	0.00267	0.00452	CcSEcCtD
Mivacurium—Angiopathy—Goserelin—prostate cancer	0.00264	0.00447	CcSEcCtD
Mivacurium—Immune system disorder—Goserelin—prostate cancer	0.00263	0.00445	CcSEcCtD
Mivacurium—Angiopathy—Conjugated Estrogens—prostate cancer	0.00262	0.00442	CcSEcCtD
Mivacurium—Immune system disorder—Conjugated Estrogens—prostate cancer	0.0026	0.0044	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.0026	0.0044	CcSEcCtD
Mivacurium—Arrhythmia—Goserelin—prostate cancer	0.0026	0.0044	CcSEcCtD
Mivacurium—Mediastinal disorder—Conjugated Estrogens—prostate cancer	0.0026	0.00439	CcSEcCtD
Mivacurium—Rash—Nilutamide—prostate cancer	0.0026	0.00439	CcSEcCtD
Mivacurium—Dermatitis—Nilutamide—prostate cancer	0.00259	0.00439	CcSEcCtD
Mivacurium—Rash—Flutamide—prostate cancer	0.00259	0.00437	CcSEcCtD
Mivacurium—Dermatitis—Flutamide—prostate cancer	0.00258	0.00437	CcSEcCtD
Mivacurium—Arrhythmia—Conjugated Estrogens—prostate cancer	0.00258	0.00436	CcSEcCtD
Mivacurium—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00256	0.00433	CcSEcCtD
Mivacurium—Erythema—Goserelin—prostate cancer	0.00253	0.00428	CcSEcCtD
Mivacurium—Erythema—Conjugated Estrogens—prostate cancer	0.00251	0.00424	CcSEcCtD
Mivacurium—Phlebitis—Docetaxel—prostate cancer	0.00249	0.00422	CcSEcCtD
Mivacurium—Skin disorder—Ethinyl Estradiol—prostate cancer	0.00244	0.00413	CcSEcCtD
Mivacurium—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00244	0.00413	CcSEcCtD
Mivacurium—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00244	0.00412	CcSEcCtD
Mivacurium—Muscle spasms—Goserelin—prostate cancer	0.00244	0.00412	CcSEcCtD
Mivacurium—Dizziness—Degarelix—prostate cancer	0.00243	0.00411	CcSEcCtD
Mivacurium—Phlebitis—Capecitabine—prostate cancer	0.00242	0.00408	CcSEcCtD
Mivacurium—Muscle spasms—Conjugated Estrogens—prostate cancer	0.00241	0.00408	CcSEcCtD
Mivacurium—Urticaria—Bicalutamide—prostate cancer	0.00236	0.00399	CcSEcCtD
Mivacurium—Rash—Degarelix—prostate cancer	0.00232	0.00392	CcSEcCtD
Mivacurium—Dermatitis—Degarelix—prostate cancer	0.00232	0.00392	CcSEcCtD
Mivacurium—Dizziness—Cabazitaxel—prostate cancer	0.00229	0.00388	CcSEcCtD
Mivacurium—Bronchospasm—Etoposide—prostate cancer	0.0022	0.00372	CcSEcCtD
Mivacurium—Bradycardia—Mitoxantrone—prostate cancer	0.00219	0.0037	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.00214	0.00362	CcSEcCtD
Mivacurium—Flushing—Estradiol—prostate cancer	0.00214	0.00362	CcSEcCtD
Mivacurium—Cardiac disorder—Estradiol—prostate cancer	0.00214	0.00362	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.00212	0.00359	CcSEcCtD
Mivacurium—BCHE—lymph node—prostate cancer	0.00211	0.0113	CbGeAlD
Mivacurium—Angiopathy—Estradiol—prostate cancer	0.00209	0.00354	CcSEcCtD
Mivacurium—Immune system disorder—Estradiol—prostate cancer	0.00208	0.00352	CcSEcCtD
Mivacurium—Mediastinal disorder—Estradiol—prostate cancer	0.00208	0.00352	CcSEcCtD
Mivacurium—Anaphylactic shock—Goserelin—prostate cancer	0.00207	0.0035	CcSEcCtD
Mivacurium—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.00205	0.00346	CcSEcCtD
Mivacurium—Tachycardia—Goserelin—prostate cancer	0.00202	0.00341	CcSEcCtD
Mivacurium—Erythema—Estradiol—prostate cancer	0.00201	0.0034	CcSEcCtD
Mivacurium—Skin disorder—Goserelin—prostate cancer	0.00201	0.0034	CcSEcCtD
Mivacurium—Tachycardia—Conjugated Estrogens—prostate cancer	0.002	0.00338	CcSEcCtD
Mivacurium—Urticaria—Ethinyl Estradiol—prostate cancer	0.002	0.00338	CcSEcCtD
Mivacurium—Skin disorder—Conjugated Estrogens—prostate cancer	0.00199	0.00336	CcSEcCtD
Mivacurium—Injection site reaction—Epirubicin—prostate cancer	0.00199	0.00336	CcSEcCtD
Mivacurium—Dizziness—Bicalutamide—prostate cancer	0.00197	0.00332	CcSEcCtD
Mivacurium—Hypotension—Goserelin—prostate cancer	0.00193	0.00327	CcSEcCtD
Mivacurium—Muscle spasms—Estradiol—prostate cancer	0.00193	0.00327	CcSEcCtD
Mivacurium—Arrhythmia—Mitoxantrone—prostate cancer	0.00192	0.00325	CcSEcCtD
Mivacurium—Hypotension—Conjugated Estrogens—prostate cancer	0.00191	0.00324	CcSEcCtD
Mivacurium—Rash—Bicalutamide—prostate cancer	0.00187	0.00317	CcSEcCtD
Mivacurium—Dermatitis—Bicalutamide—prostate cancer	0.00187	0.00317	CcSEcCtD
Mivacurium—Erythema—Mitoxantrone—prostate cancer	0.00187	0.00317	CcSEcCtD
Mivacurium—Injection site reaction—Doxorubicin—prostate cancer	0.00184	0.00311	CcSEcCtD
Mivacurium—Bronchospasm—Docetaxel—prostate cancer	0.00183	0.00309	CcSEcCtD
Mivacurium—Bronchospasm—Capecitabine—prostate cancer	0.00177	0.00299	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.0017	0.00287	CcSEcCtD
Mivacurium—Phlebitis—Epirubicin—prostate cancer	0.00168	0.00284	CcSEcCtD
Mivacurium—Dizziness—Ethinyl Estradiol—prostate cancer	0.00166	0.00281	CcSEcCtD
Mivacurium—Flushing—Etoposide—prostate cancer	0.00166	0.00281	CcSEcCtD
Mivacurium—Cardiac disorder—Etoposide—prostate cancer	0.00166	0.00281	CcSEcCtD
Mivacurium—Urticaria—Goserelin—prostate cancer	0.00164	0.00278	CcSEcCtD
Mivacurium—Anaphylactic shock—Estradiol—prostate cancer	0.00164	0.00277	CcSEcCtD
Mivacurium—Urticaria—Conjugated Estrogens—prostate cancer	0.00163	0.00275	CcSEcCtD
Mivacurium—Angiopathy—Etoposide—prostate cancer	0.00162	0.00274	CcSEcCtD
Mivacurium—Immune system disorder—Etoposide—prostate cancer	0.00162	0.00273	CcSEcCtD
Mivacurium—Mediastinal disorder—Etoposide—prostate cancer	0.00161	0.00273	CcSEcCtD
Mivacurium—Tachycardia—Estradiol—prostate cancer	0.0016	0.00271	CcSEcCtD
Mivacurium—Skin disorder—Estradiol—prostate cancer	0.00159	0.00269	CcSEcCtD
Mivacurium—Rash—Ethinyl Estradiol—prostate cancer	0.00158	0.00268	CcSEcCtD
Mivacurium—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00158	0.00268	CcSEcCtD
Mivacurium—Phlebitis—Doxorubicin—prostate cancer	0.00156	0.00263	CcSEcCtD
Mivacurium—Anaphylactic shock—Mitoxantrone—prostate cancer	0.00153	0.00258	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Epirubicin—prostate cancer	0.0015	0.00253	CcSEcCtD
Mivacurium—Muscle spasms—Etoposide—prostate cancer	0.0015	0.00253	CcSEcCtD
Mivacurium—Tachycardia—Mitoxantrone—prostate cancer	0.00149	0.00252	CcSEcCtD
Mivacurium—Skin disorder—Mitoxantrone—prostate cancer	0.00148	0.00251	CcSEcCtD
Mivacurium—Bradycardia—Capecitabine—prostate cancer	0.00147	0.00248	CcSEcCtD
Mivacurium—Hypotension—Mitoxantrone—prostate cancer	0.00143	0.00241	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.00139	0.00234	CcSEcCtD
Mivacurium—Cardiac disorder—Docetaxel—prostate cancer	0.00138	0.00233	CcSEcCtD
Mivacurium—Flushing—Docetaxel—prostate cancer	0.00138	0.00233	CcSEcCtD
Mivacurium—Dizziness—Goserelin—prostate cancer	0.00137	0.00231	CcSEcCtD
Mivacurium—Dizziness—Conjugated Estrogens—prostate cancer	0.00135	0.00229	CcSEcCtD
Mivacurium—Angiopathy—Docetaxel—prostate cancer	0.00135	0.00228	CcSEcCtD
Mivacurium—Immune system disorder—Docetaxel—prostate cancer	0.00134	0.00227	CcSEcCtD
Mivacurium—Mediastinal disorder—Docetaxel—prostate cancer	0.00134	0.00227	CcSEcCtD
Mivacurium—Flushing—Capecitabine—prostate cancer	0.00134	0.00226	CcSEcCtD
Mivacurium—Cardiac disorder—Capecitabine—prostate cancer	0.00134	0.00226	CcSEcCtD
Mivacurium—Arrhythmia—Docetaxel—prostate cancer	0.00133	0.00225	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.00132	0.00223	CcSEcCtD
Mivacurium—Angiopathy—Capecitabine—prostate cancer	0.00131	0.00221	CcSEcCtD
Mivacurium—Bradycardia—Prednisone—prostate cancer	0.00131	0.00221	CcSEcCtD
Mivacurium—Rash—Goserelin—prostate cancer	0.0013	0.0022	CcSEcCtD
Mivacurium—Dermatitis—Goserelin—prostate cancer	0.0013	0.0022	CcSEcCtD
Mivacurium—Urticaria—Estradiol—prostate cancer	0.0013	0.0022	CcSEcCtD
Mivacurium—Immune system disorder—Capecitabine—prostate cancer	0.0013	0.0022	CcSEcCtD
Mivacurium—Mediastinal disorder—Capecitabine—prostate cancer	0.0013	0.00219	CcSEcCtD
Mivacurium—Erythema—Docetaxel—prostate cancer	0.00129	0.00219	CcSEcCtD
Mivacurium—Rash—Conjugated Estrogens—prostate cancer	0.00129	0.00218	CcSEcCtD
Mivacurium—Dermatitis—Conjugated Estrogens—prostate cancer	0.00129	0.00218	CcSEcCtD
Mivacurium—Arrhythmia—Capecitabine—prostate cancer	0.00129	0.00217	CcSEcCtD
Mivacurium—Anaphylactic shock—Etoposide—prostate cancer	0.00127	0.00215	CcSEcCtD
Mivacurium—Erythema—Capecitabine—prostate cancer	0.00125	0.00212	CcSEcCtD
Mivacurium—Muscle spasms—Docetaxel—prostate cancer	0.00124	0.0021	CcSEcCtD
Mivacurium—Tachycardia—Etoposide—prostate cancer	0.00124	0.0021	CcSEcCtD
Mivacurium—Skin disorder—Etoposide—prostate cancer	0.00123	0.00209	CcSEcCtD
Mivacurium—Urticaria—Mitoxantrone—prostate cancer	0.00121	0.00205	CcSEcCtD
Mivacurium—Muscle spasms—Capecitabine—prostate cancer	0.0012	0.00204	CcSEcCtD
Mivacurium—Flushing—Prednisone—prostate cancer	0.00119	0.00201	CcSEcCtD
Mivacurium—Hypotension—Etoposide—prostate cancer	0.00119	0.00201	CcSEcCtD
Mivacurium—Angiopathy—Prednisone—prostate cancer	0.00116	0.00197	CcSEcCtD
Mivacurium—Immune system disorder—Prednisone—prostate cancer	0.00116	0.00196	CcSEcCtD
Mivacurium—Arrhythmia—Prednisone—prostate cancer	0.00115	0.00194	CcSEcCtD
Mivacurium—Erythema—Prednisone—prostate cancer	0.00112	0.00189	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00109	0.00185	CcSEcCtD
Mivacurium—Dizziness—Estradiol—prostate cancer	0.00108	0.00183	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.00106	0.00179	CcSEcCtD
Mivacurium—Anaphylactic shock—Docetaxel—prostate cancer	0.00106	0.00179	CcSEcCtD
Mivacurium—Rash—Estradiol—prostate cancer	0.00103	0.00175	CcSEcCtD
Mivacurium—Dermatitis—Estradiol—prostate cancer	0.00103	0.00175	CcSEcCtD
Mivacurium—Tachycardia—Docetaxel—prostate cancer	0.00103	0.00174	CcSEcCtD
Mivacurium—Skin disorder—Docetaxel—prostate cancer	0.00103	0.00173	CcSEcCtD
Mivacurium—Bradycardia—Epirubicin—prostate cancer	0.00102	0.00173	CcSEcCtD
Mivacurium—Urticaria—Etoposide—prostate cancer	0.00101	0.00171	CcSEcCtD
Mivacurium—Tachycardia—Capecitabine—prostate cancer	0.000998	0.00169	CcSEcCtD
Mivacurium—Skin disorder—Capecitabine—prostate cancer	0.000993	0.00168	CcSEcCtD
Mivacurium—Hypotension—Docetaxel—prostate cancer	0.000987	0.00167	CcSEcCtD
Mivacurium—Rash—Mitoxantrone—prostate cancer	0.000963	0.00163	CcSEcCtD
Mivacurium—Dermatitis—Mitoxantrone—prostate cancer	0.000963	0.00163	CcSEcCtD
Mivacurium—Hypotension—Capecitabine—prostate cancer	0.000956	0.00162	CcSEcCtD
Mivacurium—Bradycardia—Doxorubicin—prostate cancer	0.000945	0.0016	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000944	0.0016	CcSEcCtD
Mivacurium—Cardiac disorder—Epirubicin—prostate cancer	0.000931	0.00157	CcSEcCtD
Mivacurium—Flushing—Epirubicin—prostate cancer	0.000931	0.00157	CcSEcCtD
Mivacurium—Anaphylactic shock—Prednisone—prostate cancer	0.000911	0.00154	CcSEcCtD
Mivacurium—Angiopathy—Epirubicin—prostate cancer	0.00091	0.00154	CcSEcCtD
Mivacurium—Immune system disorder—Epirubicin—prostate cancer	0.000906	0.00153	CcSEcCtD
Mivacurium—Mediastinal disorder—Epirubicin—prostate cancer	0.000904	0.00153	CcSEcCtD
Mivacurium—Arrhythmia—Epirubicin—prostate cancer	0.000896	0.00151	CcSEcCtD
Mivacurium—Tachycardia—Prednisone—prostate cancer	0.000889	0.0015	CcSEcCtD
Mivacurium—Skin disorder—Prednisone—prostate cancer	0.000885	0.0015	CcSEcCtD
Mivacurium—Erythema—Epirubicin—prostate cancer	0.000873	0.00148	CcSEcCtD
Mivacurium—Cardiac disorder—Doxorubicin—prostate cancer	0.000861	0.00146	CcSEcCtD
Mivacurium—Flushing—Doxorubicin—prostate cancer	0.000861	0.00146	CcSEcCtD
Mivacurium—Angiopathy—Doxorubicin—prostate cancer	0.000842	0.00142	CcSEcCtD
Mivacurium—Dizziness—Etoposide—prostate cancer	0.00084	0.00142	CcSEcCtD
Mivacurium—Muscle spasms—Epirubicin—prostate cancer	0.000839	0.00142	CcSEcCtD
Mivacurium—Immune system disorder—Doxorubicin—prostate cancer	0.000838	0.00142	CcSEcCtD
Mivacurium—Mediastinal disorder—Doxorubicin—prostate cancer	0.000836	0.00141	CcSEcCtD
Mivacurium—Arrhythmia—Doxorubicin—prostate cancer	0.000829	0.0014	CcSEcCtD
Mivacurium—Urticaria—Capecitabine—prostate cancer	0.000812	0.00137	CcSEcCtD
Mivacurium—Erythema—Doxorubicin—prostate cancer	0.000808	0.00137	CcSEcCtD
Mivacurium—Rash—Etoposide—prostate cancer	0.000801	0.00135	CcSEcCtD
Mivacurium—Dermatitis—Etoposide—prostate cancer	0.000801	0.00135	CcSEcCtD
Mivacurium—Muscle spasms—Doxorubicin—prostate cancer	0.000777	0.00131	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000738	0.00125	CcSEcCtD
Mivacurium—Urticaria—Prednisone—prostate cancer	0.000724	0.00122	CcSEcCtD
Mivacurium—Anaphylactic shock—Epirubicin—prostate cancer	0.000712	0.0012	CcSEcCtD
Mivacurium—Dizziness—Docetaxel—prostate cancer	0.000698	0.00118	CcSEcCtD
Mivacurium—Tachycardia—Epirubicin—prostate cancer	0.000695	0.00118	CcSEcCtD
Mivacurium—Skin disorder—Epirubicin—prostate cancer	0.000692	0.00117	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000683	0.00115	CcSEcCtD
Mivacurium—Dizziness—Capecitabine—prostate cancer	0.000676	0.00114	CcSEcCtD
Mivacurium—Rash—Docetaxel—prostate cancer	0.000666	0.00113	CcSEcCtD
Mivacurium—Hypotension—Epirubicin—prostate cancer	0.000666	0.00113	CcSEcCtD
Mivacurium—Dermatitis—Docetaxel—prostate cancer	0.000665	0.00112	CcSEcCtD
Mivacurium—Anaphylactic shock—Doxorubicin—prostate cancer	0.000659	0.00111	CcSEcCtD
Mivacurium—Rash—Capecitabine—prostate cancer	0.000645	0.00109	CcSEcCtD
Mivacurium—Dermatitis—Capecitabine—prostate cancer	0.000644	0.00109	CcSEcCtD
Mivacurium—Tachycardia—Doxorubicin—prostate cancer	0.000643	0.00109	CcSEcCtD
Mivacurium—Skin disorder—Doxorubicin—prostate cancer	0.00064	0.00108	CcSEcCtD
Mivacurium—Hypotension—Doxorubicin—prostate cancer	0.000616	0.00104	CcSEcCtD
Mivacurium—Dizziness—Prednisone—prostate cancer	0.000602	0.00102	CcSEcCtD
Mivacurium—Rash—Prednisone—prostate cancer	0.000574	0.000971	CcSEcCtD
Mivacurium—Dermatitis—Prednisone—prostate cancer	0.000574	0.00097	CcSEcCtD
Mivacurium—Urticaria—Epirubicin—prostate cancer	0.000566	0.000957	CcSEcCtD
Mivacurium—Urticaria—Doxorubicin—prostate cancer	0.000524	0.000885	CcSEcCtD
Mivacurium—Dizziness—Epirubicin—prostate cancer	0.000471	0.000796	CcSEcCtD
Mivacurium—Rash—Epirubicin—prostate cancer	0.000449	0.000759	CcSEcCtD
Mivacurium—Dermatitis—Epirubicin—prostate cancer	0.000449	0.000759	CcSEcCtD
Mivacurium—Dizziness—Doxorubicin—prostate cancer	0.000436	0.000737	CcSEcCtD
Mivacurium—Rash—Doxorubicin—prostate cancer	0.000416	0.000703	CcSEcCtD
Mivacurium—Dermatitis—Doxorubicin—prostate cancer	0.000415	0.000702	CcSEcCtD
Mivacurium—CHRM2—Signaling Pathways—HIST1H4H—prostate cancer	5.2e-05	0.000235	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—CXCL8—prostate cancer	5.2e-05	0.000234	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP17A1—prostate cancer	5.17e-05	0.000233	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—RXRA—prostate cancer	5.14e-05	0.000232	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GNG5—prostate cancer	5.12e-05	0.000231	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GNG5—prostate cancer	5.07e-05	0.000229	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5e-05	0.000225	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—COMT—prostate cancer	4.95e-05	0.000223	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NCOA2—prostate cancer	4.93e-05	0.000222	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GSTP1—prostate cancer	4.92e-05	0.000222	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ITPR1—prostate cancer	4.84e-05	0.000219	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—CXCL8—prostate cancer	4.8e-05	0.000217	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.76e-05	0.000215	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SLC5A5—prostate cancer	4.7e-05	0.000212	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP2E1—prostate cancer	4.59e-05	0.000207	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—TYMS—prostate cancer	4.58e-05	0.000206	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NQO1—prostate cancer	4.54e-05	0.000205	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GSTM1—prostate cancer	4.52e-05	0.000204	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—TH—prostate cancer	4.47e-05	0.000202	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFBR1—prostate cancer	4.46e-05	0.000201	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTHLH—prostate cancer	4.46e-05	0.000201	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—LPL—prostate cancer	4.44e-05	0.0002	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—CTNNB1—prostate cancer	4.43e-05	0.0002	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP3A4—prostate cancer	4.43e-05	0.0002	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTHLH—prostate cancer	4.42e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFBR1—prostate cancer	4.42e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKR1C3—prostate cancer	4.39e-05	0.000198	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRKACB—prostate cancer	4.37e-05	0.000197	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP1B1—prostate cancer	4.35e-05	0.000196	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKR1C3—prostate cancer	4.35e-05	0.000196	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRKACB—prostate cancer	4.33e-05	0.000195	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CYP1A1—prostate cancer	4.29e-05	0.000193	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PPP3CA—prostate cancer	4.26e-05	0.000192	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—THBS1—prostate cancer	4.26e-05	0.000192	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ERCC2—prostate cancer	4.25e-05	0.000192	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PPP3CA—prostate cancer	4.22e-05	0.00019	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—THBS1—prostate cancer	4.22e-05	0.00019	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GGT1—prostate cancer	4.22e-05	0.00019	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ANXA1—prostate cancer	4.2e-05	0.000189	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ANXA1—prostate cancer	4.16e-05	0.000187	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NCOA1—prostate cancer	4.15e-05	0.000187	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRKCZ—prostate cancer	4.12e-05	0.000186	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP19A1—prostate cancer	4.09e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRKCZ—prostate cancer	4.08e-05	0.000184	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CG—prostate cancer	4.03e-05	0.000182	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—MTHFR—prostate cancer	4e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CG—prostate cancer	3.99e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PARP1—prostate cancer	3.98e-05	0.000179	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGFR4—prostate cancer	3.98e-05	0.000179	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—RXRA—prostate cancer	3.95e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PARP1—prostate cancer	3.94e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGFR4—prostate cancer	3.94e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CALCA—prostate cancer	3.93e-05	0.000177	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PPARA—prostate cancer	3.92e-05	0.000177	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CALCA—prostate cancer	3.89e-05	0.000176	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL12—prostate cancer	3.84e-05	0.000173	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—COMT—prostate cancer	3.8e-05	0.000172	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL12—prostate cancer	3.8e-05	0.000171	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTP1—prostate cancer	3.79e-05	0.000171	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ITPR1—prostate cancer	3.73e-05	0.000168	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CAV1—prostate cancer	3.69e-05	0.000166	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CG—prostate cancer	3.66e-05	0.000165	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CG—prostate cancer	3.62e-05	0.000163	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP9—prostate cancer	3.62e-05	0.000163	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP9—prostate cancer	3.58e-05	0.000161	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CD—prostate cancer	3.54e-05	0.00016	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.52e-05	0.000159	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—TYMS—prostate cancer	3.52e-05	0.000159	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CD—prostate cancer	3.51e-05	0.000158	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRKCQ—prostate cancer	3.5e-05	0.000158	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NGFR—prostate cancer	3.5e-05	0.000158	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTM1—prostate cancer	3.48e-05	0.000157	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRKCQ—prostate cancer	3.47e-05	0.000156	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NGFR—prostate cancer	3.47e-05	0.000156	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MAP3K7—prostate cancer	3.46e-05	0.000156	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MAP3K7—prostate cancer	3.43e-05	0.000155	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—LPL—prostate cancer	3.42e-05	0.000154	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CG—prostate cancer	3.36e-05	0.000152	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF10—prostate cancer	3.33e-05	0.00015	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP1A1—prostate cancer	3.3e-05	0.000149	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF10—prostate cancer	3.3e-05	0.000149	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADRB2—prostate cancer	3.29e-05	0.000149	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ERCC2—prostate cancer	3.27e-05	0.000148	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADRB2—prostate cancer	3.26e-05	0.000147	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—JAK2—prostate cancer	3.25e-05	0.000147	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—MAP2K1—prostate cancer	3.24e-05	0.000146	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	3.22e-05	0.000145	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CD—prostate cancer	3.21e-05	0.000145	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VAV3—prostate cancer	3.21e-05	0.000145	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	3.2e-05	0.000145	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	3.18e-05	0.000144	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VAV3—prostate cancer	3.18e-05	0.000143	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—INS—prostate cancer	3.18e-05	0.000143	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFBR2—prostate cancer	3.17e-05	0.000143	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	3.14e-05	0.000141	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ITPR1—prostate cancer	3.12e-05	0.000141	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CREBBP—prostate cancer	3.12e-05	0.000141	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CB—prostate cancer	3.09e-05	0.000139	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ITPR1—prostate cancer	3.09e-05	0.000139	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—MTHFR—prostate cancer	3.07e-05	0.000139	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	3.06e-05	0.000138	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PPARA—prostate cancer	3.02e-05	0.000136	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1R—prostate cancer	2.98e-05	0.000134	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CXCL8—prostate cancer	2.97e-05	0.000134	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CD—prostate cancer	2.95e-05	0.000133	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—JAK2—prostate cancer	2.95e-05	0.000133	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1R—prostate cancer	2.95e-05	0.000133	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	2.94e-05	0.000132	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—JAK2—prostate cancer	2.92e-05	0.000132	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—LPL—prostate cancer	2.86e-05	0.000129	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CAV1—prostate cancer	2.84e-05	0.000128	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—IL2—prostate cancer	2.83e-05	0.000128	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PDGFRB—prostate cancer	2.83e-05	0.000128	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—LPL—prostate cancer	2.83e-05	0.000128	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—IL2—prostate cancer	2.81e-05	0.000127	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	2.8e-05	0.000126	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CB—prostate cancer	2.8e-05	0.000126	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—NOS3—prostate cancer	2.79e-05	0.000126	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	2.77e-05	0.000125	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ITGB3—prostate cancer	2.76e-05	0.000124	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ITGB3—prostate cancer	2.73e-05	0.000123	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	2.69e-05	0.000121	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB3—prostate cancer	2.68e-05	0.000121	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGFR2—prostate cancer	2.67e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	2.67e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB3—prostate cancer	2.65e-05	0.000119	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGFR2—prostate cancer	2.65e-05	0.000119	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CG—prostate cancer	2.58e-05	0.000117	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CB—prostate cancer	2.57e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL2—prostate cancer	2.57e-05	0.000116	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TERT—prostate cancer	2.56e-05	0.000116	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTGS2—prostate cancer	2.55e-05	0.000115	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL2—prostate cancer	2.55e-05	0.000115	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TERT—prostate cancer	2.54e-05	0.000115	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HIF1A—prostate cancer	2.45e-05	0.000111	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—INS—prostate cancer	2.45e-05	0.00011	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HIF1A—prostate cancer	2.43e-05	0.00011	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CREBBP—prostate cancer	2.4e-05	0.000108	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—LEP—prostate cancer	2.39e-05	0.000108	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CAV1—prostate cancer	2.37e-05	0.000107	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—LEP—prostate cancer	2.37e-05	0.000107	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CAV1—prostate cancer	2.35e-05	0.000106	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KDR—prostate cancer	2.35e-05	0.000106	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KDR—prostate cancer	2.32e-05	0.000105	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ESR1—prostate cancer	2.29e-05	0.000103	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CD—prostate cancer	2.27e-05	0.000102	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ESR1—prostate cancer	2.26e-05	0.000102	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—BAD—prostate cancer	2.23e-05	0.000101	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTEN—prostate cancer	2.22e-05	0.0001	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—BAD—prostate cancer	2.21e-05	9.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APC—prostate cancer	2.16e-05	9.74e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	2.16e-05	9.74e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NOS3—prostate cancer	2.14e-05	9.67e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	2.14e-05	9.65e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APC—prostate cancer	2.14e-05	9.65e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGF—prostate cancer	2.14e-05	9.63e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IRS1—prostate cancer	2.14e-05	9.63e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—EP300—prostate cancer	2.12e-05	9.57e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGF—prostate cancer	2.11e-05	9.54e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IRS1—prostate cancer	2.11e-05	9.54e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GSK3B—prostate cancer	2.07e-05	9.35e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GSK3B—prostate cancer	2.05e-05	9.26e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—INS—prostate cancer	2.04e-05	9.22e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—INS—prostate cancer	2.03e-05	9.13e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CREBBP—prostate cancer	2e-05	9.03e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CREBBP—prostate cancer	1.98e-05	8.95e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CB—prostate cancer	1.98e-05	8.93e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1—prostate cancer	1.98e-05	8.92e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—EGFR—prostate cancer	1.97e-05	8.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTGS2—prostate cancer	1.96e-05	8.85e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1—prostate cancer	1.96e-05	8.84e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—EGFR—prostate cancer	1.95e-05	8.79e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	1.91e-05	8.62e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	1.9e-05	8.57e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	1.89e-05	8.54e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	1.88e-05	8.48e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	1.88e-05	8.48e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	1.88e-05	8.47e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	1.86e-05	8.4e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	1.86e-05	8.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—KRAS—prostate cancer	1.86e-05	8.39e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—KRAS—prostate cancer	1.84e-05	8.31e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF2—prostate cancer	1.82e-05	8.2e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF2—prostate cancer	1.8e-05	8.12e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOS3—prostate cancer	1.79e-05	8.09e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOS3—prostate cancer	1.78e-05	8.01e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—JAK2—prostate cancer	1.74e-05	7.86e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JAK2—prostate cancer	1.73e-05	7.79e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTEN—prostate cancer	1.71e-05	7.72e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	1.71e-05	7.71e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MDM2—prostate cancer	1.7e-05	7.67e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	1.69e-05	7.63e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MDM2—prostate cancer	1.68e-05	7.6e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ERBB2—prostate cancer	1.68e-05	7.57e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ERBB2—prostate cancer	1.66e-05	7.49e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	1.66e-05	7.47e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	1.64e-05	7.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—EP300—prostate cancer	1.63e-05	7.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL8—prostate cancer	1.59e-05	7.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL8—prostate cancer	1.58e-05	7.11e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3CA—prostate cancer	1.57e-05	7.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	1.55e-05	7.01e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	1.54e-05	6.94e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	1.54e-05	6.93e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP3—prostate cancer	1.52e-05	6.87e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	1.52e-05	6.86e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL2—prostate cancer	1.52e-05	6.86e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL6—prostate cancer	1.51e-05	6.82e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP3—prostate cancer	1.51e-05	6.8e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL2—prostate cancer	1.51e-05	6.79e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.5e-05	6.76e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCND1—prostate cancer	1.48e-05	6.68e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.47e-05	6.62e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	1.47e-05	6.62e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.45e-05	6.56e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP9—prostate cancer	1.44e-05	6.49e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.43e-05	6.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.43e-05	6.45e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.42e-05	6.43e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.42e-05	6.4e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.42e-05	6.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.4e-05	6.29e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.38e-05	6.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EP300—prostate cancer	1.36e-05	6.15e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EP300—prostate cancer	1.35e-05	6.09e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SRC—prostate cancer	1.33e-05	5.98e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SRC—prostate cancer	1.31e-05	5.93e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VEGFA—prostate cancer	1.29e-05	5.83e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AKT1—prostate cancer	1.28e-05	5.78e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.28e-05	5.77e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STAT3—prostate cancer	1.28e-05	5.77e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.27e-05	5.71e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3CA—prostate cancer	1.21e-05	5.44e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MYC—prostate cancer	1.19e-05	5.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFB1—prostate cancer	1.19e-05	5.35e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MYC—prostate cancer	1.18e-05	5.31e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.17e-05	5.3e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGFR—prostate cancer	1.16e-05	5.24e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.15e-05	5.19e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KRAS—prostate cancer	1.1e-05	4.95e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.09e-05	4.91e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	1.01e-05	4.55e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	9.99e-06	4.51e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AKT1—prostate cancer	9.86e-06	4.45e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TP53—prostate cancer	9.76e-06	4.4e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TP53—prostate cancer	9.67e-06	4.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL6—prostate cancer	8.94e-06	4.03e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL6—prostate cancer	8.85e-06	3.99e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT1—prostate cancer	8.24e-06	3.72e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT1—prostate cancer	8.16e-06	3.68e-05	CbGpPWpGaD
